APA (7th ed.) Citation

V, N., F, L., LG, B., KE, S., M, A., S, D. R., . . . Z, M. (2024). Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial. PLOS global public health, 4(9), e0003319. https://doi.org/10.1371/journal.pgph.0003319

Chicago Style (17th ed.) Citation

V, Naicker, et al. "Safety and Immunogenicity After a 30-month Boost of a Subtype C ALVAC-HIV (vCP2438) Vaccine Prime Plus Bivalent Subtype C Gp120/MF59 Vaccine Boost (HVTN 100): A Phase 1-2 Randomized Double-blind Placebo-controlled Trial." PLOS Global Public Health 4, no. 9 (2024): e0003319. https://doi.org/10.1371/journal.pgph.0003319.

MLA (9th ed.) Citation

V, Naicker, et al. "Safety and Immunogenicity After a 30-month Boost of a Subtype C ALVAC-HIV (vCP2438) Vaccine Prime Plus Bivalent Subtype C Gp120/MF59 Vaccine Boost (HVTN 100): A Phase 1-2 Randomized Double-blind Placebo-controlled Trial." PLOS Global Public Health, vol. 4, no. 9, 2024, p. e0003319, https://doi.org/10.1371/journal.pgph.0003319.